Loading
REL (Proto-oncogene c-Rel) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Diffuse large B-cell lymphoma.
Proto-oncogene that may play a role in differentiation and lymphopoiesis. NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52.
CIViC holds 1 clinical evidence item and 0 assertions across 2 variants. Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.80, animal model 0.51, genetic association 0.00, somatic mutation 0.96).
In plain words · REL (Proto-oncogene c-Rel) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Diffuse large B-cell lymphoma.
REL (Proto-oncogene c-Rel) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Diffuse large B-cell lymphoma.
Proto-oncogene that may play a role in differentiation and lymphopoiesis.
No product in this corpus aims at REL yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA REL: RNA tissue enhanced (bone marrow 35 nTPM); no normal tissue stained high; highest cancer staining skin cancer (7 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Ovarian cancer, Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas REL tissue; Open Targets ENSG00000162924 associations
First described 1985. Earliest sequence paper UniProt cites for the protein: Brownell et al, Mol. Cell. Biol, 1985, "Genetic characterization of human c-rel sequences". Source.
Sources: HGNC HGNC:9954 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q04864 (protein name, function text, keywords and locations (REST API)); CIViC gene REL (1 evidence items, 0 assertions, 2 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000162924 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: ovarian cancer 0.50 (GraphQL API, CC0))
Proto-oncogene that may play a role in differentiation and lymphopoiesis. NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalisation as well as by interactions with other cofactors or corepressors. Location: Nucleus (UniProt). Locus 2p16.1 (HGNC).
RNA: tissue enhanced (bone marrow 35 nTPM), detected in all normal tissues.
No normal tissue stained high.
Medium only: breast cancer, pancreatic cancer, prostate cancer, renal cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"REL" OR ABSTRACT:"REL" OR TITLE:"REL proto-oncogene, NF-kB subunit" OR ABSTRACT:"REL proto-oncogene, NF-kB subunit" OR TITLE:"Proto-oncogene c-Rel" OR ABSTRACT:"Proto-oncogene c-Rel" OR TITLE:"I-Rel" OR ABSTRACT:"I-Rel" OR TITLE:"c-Rel" OR ABSTRACT:"c-Rel" OR TITLE:"HIVEN86A" OR ABSTRACT:"HIVEN86A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about REL, not a curated reading list.